GRAIL (NASDAQ:GRAL) Insider Sells $91,070.28 in Stock

GRAIL, Inc. (NASDAQ:GRAL) insider Andrew John Partridge sold 1,491 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the sale, the insider owned 163,738 shares of the company’s stock, valued at $10,001,117.04. This represents a 0.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

GRAIL Price Performance

Shares of NASDAQ:GRAL traded down $6.57 during trading on Friday, hitting $59.98. 760,283 shares of the company’s stock were exchanged, compared to its average volume of 809,610. GRAIL, Inc. has a 52-week low of $29.95 and a 52-week high of $118.84. The business’s 50-day simple moving average is $57.27 and its 200 day simple moving average is $75.49. The company has a market cap of $2.57 billion, a price-to-earnings ratio of -5.78 and a beta of 3.15.

GRAIL (NASDAQ:GRAL) last released its earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The firm had revenue of $40.79 million during the quarter, compared to analysts’ expectations of $39.16 million. On average, sell-side analysts anticipate that GRAIL, Inc. will post -10.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GRAL has been the subject of several research analyst reports. Mizuho initiated coverage on GRAIL in a research report on Friday, April 10th. They set a “neutral” rating and a $58.00 target price for the company. Piper Sandler increased their target price on GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Wolfe Research initiated coverage on GRAIL in a research report on Tuesday. They set a “peer perform” rating for the company. Canaccord Genuity Group cut their target price on GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Finally, Robert W. Baird set a $70.00 target price on GRAIL in a research report on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, GRAIL currently has an average rating of “Hold” and an average price target of $67.00.

Hedge Funds Weigh In On GRAIL

Several institutional investors have recently added to or reduced their stakes in GRAL. Farallon Capital Management LLC lifted its stake in shares of GRAIL by 73.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after purchasing an additional 993,684 shares during the last quarter. Baker BROS. Advisors LP lifted its stake in shares of GRAIL by 27.9% in the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after purchasing an additional 455,208 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of GRAIL by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock valued at $169,535,000 after purchasing an additional 163,790 shares during the last quarter. State Street Corp lifted its stake in shares of GRAIL by 38.8% in the 4th quarter. State Street Corp now owns 1,827,523 shares of the company’s stock valued at $156,418,000 after purchasing an additional 510,546 shares during the last quarter. Finally, Morgan Stanley lifted its stake in shares of GRAIL by 63.8% in the 4th quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock valued at $129,385,000 after purchasing an additional 588,647 shares during the last quarter.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.